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Abstract
The aim of the study was to evaluate dynamic contrast-enhanced breast magnetic resonance imaging (DCE-MRI) features for the
prediction of early and late recurrences in patients with breast cancer.
Of 1030 breast cancer patients who underwent surgery at our hospital from January 2007 to July 2011, 83 recurrent breast cancer
patients were enrolled in this study. We compared MRI features (background parenchymal enhancement [BPE], internal
enhancement, adjacent vessel sign, whole-breast vascularity, initial enhancement pattern, kinetic curve types, and quantitative
kinetic parameters) and clinico-pathologic variables (age, stage, histologic grade, nuclear grade, existence of lymphovascular
invasion and extensive intraductal carcinoma component, and immunohistochemical proﬁles) between patients with early (2.5
years after surgery) and late recurrence (>2.5 years after surgery). Cox proportional hazard regression analysis was performed to
evaluate independent risk factors for early and late recurrence.
On breast MRI, prominent ipsilateral whole-breast vascularity was independently associated with early recurrence (hazard ratio
[HR], 2.86; 95% conﬁdence intervals [CI], 1.39–5.88) and moderate or marked BPE (HR, 2.08; 95% CI, 1.04–4.18) and rim
enhancement (HR, 2.14; 95% CI, 1.00–4.59) were independently associated with late recurrence. Clinico-pathologic variables
independently associated with early recurrence included negative estrogen receptor (HR, 0.53; 95% CI, 0.29–0.96), whereas T2
stage (HR, 2.08; 95% CI, 1.04–4.16) and nuclear grade III (HR, 2.54; 95% CI, 1.29–4.98) were associated with late recurrence.
In DCE-MRI, prominent ipsilateral whole-breast vascularity, moderate or marked BPE, and rim enhancement could be useful for
predicting recurrence timing in patients with breast cancer.
Abbreviations: AUC = area under the receiver operating characteristic curve, BI-RADS = Breast Imaging Reporting and Data
System, BPE = background parenchymal enhancement, CI = conﬁdence interval, DCE-MRI = dynamic contrast-enhanced
magnetic resonance imaging, E1= initial enhancement percentage, Epeak= peak enhancement percentage, ER= estrogen receptor,
HER-2 = human epidermal growth factor receptor 2, HR = hazard ratio, PR = progesterone receptor, ROC = receiver-operating
characteristic, ROI = region of interest, SER = signal enhancement ratio, TTP = time to peak enhancement.
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11. Introduction
Breast cancer is one of the most common causes of cancer-related
death in women worldwide.[1] Despite advances in early
diagnosis, treatment, and biomarker identiﬁcation of this cancer,
∼20% to 30% of breast cancer patients experience recurrence
and substantially worse overall survival.[2,3] Therefore, it is
critical to identify risk factors that can predict breast cancer
recurrence.
Angiogenesis is a requirement of neoplastic growth, progres-
sion, and metastasis. For breast cancer, contrast-enhanced breast
magnetic resonance imaging (MRI) is a good imagingmodality to
depict tumor angiogenesis because the contrast enhancement
pattern of the tumor correlates with microvessel density
characteristic of tumor angiogenesis.[4,5] In addition, dynamic
contrast-enhanced MRI (DCE-MRI) features such as peripheral
rim enhancement, faster enhancement, and washout curve type
are correlated with overall recurrence and overall survival of
breast cancer patients.[6,7]
Determining predictive factors for early and late recurrences of
breast cancer has become increasingly important, considering
that ∼70% of early recurrence occurs within 3 years of diagnosis
and patients with early recurrence experience shorter median
survival and more aggressive course than those with late
recurrence.[8] Additionally, understanding when breast cancer
Choi et al. Medicine (2016) 95:48 Medicinemay recur has relevance for clinicians in selecting adjuvant
treatment options.[8–10] For example, in estrogen receptor (ER)-
positive breast cancers, which are associated with late
recurrence, selection of tamoxifen-aromatase inhibitor therapy
as adjuvant endocrine therapy can improve disease-free survival
and overall survival.[11] Patients with breast cancer showing
features associated with early recurrence would require
chemotherapy.[12] Previous studies have found that clinico-
pathologic factors such as N stage, histologic grade, nuclear
grade, p53, Ki-67, human epidermal growth factor receptor 2
(HER-2), and ER are associated with the time of recur-
rence.[13,14] To the best of our knowledge, however, DCE-MRI
features associated with the timing of breast cancer recurrence
have not yet been investigated.
The aim of the current study was to evaluate DCE-MRI
features for the prediction of early and late recurrences in patients
with breast cancer. We hypothesized that identifying DCE-MRI
features predictive of early and late recurrencemay help clinicians
establish protocol for follow-up and predict prognosis in patients
with recurrent breast cancers even before surgery.
2. Materials and methods
2.1. Study population
This retrospective study was approved by the institutional review
board of our hospital, and the requirement for informed consent
was waived. From January 2007 to July 2011, 1030 consecutive
women underwent completion of curative surgery for breast
cancer at our hospital. After surgery, adjuvant therapy such as
radiation therapy, chemotherapy, or hormonal therapy was
administered according to the patient’s condition and clinical and
molecular characteristics of the tumor. Among this population, a
total of 602 women were enrolled in this study (Fig. 1). The
inclusion criteria were as follows: (a) patients had pathologically
conﬁrmed breast cancer; (b) patients had no history of cancer inFigure 1. Flowchart of 1030 patients with brea
2the breast or at any other site; (c) patients had preoperative breast
MR imaging available; and (d) patients had no distant metastasis
at the time of diagnosis. The remaining 428 women who
underwent excisional or vacuum-assisted biopsy prior to
preoperative MR imaging (n = 163), had received neoadjuvant
chemotherapy (n=92), had clinical or pathological T4 cancer
(n=81), or were lost to follow-up (n=92) were excluded from
this study.
Breast cancer recurrence was deﬁned as either loco-regional
(limited to the ipsilateral breast or chest wall and/or axillary,
infraclavicular, or supraclavicular lymph nodes) or distant
(metastasis to other parts of the body). Follow-up was scheduled
every 6 months during the ﬁrst 2 years after surgery and annually
beginning the third year as part of the routine clinical standard of
care at our institution. All patients were examined via bilateral
mammography and bilateral whole-breast ultrasonography
using hand-held ultrasound for the surveillance of loco-regional
recurrence. Chest radiography, chest computed tomography,
bone scan, and/or whole-body ﬂuorine 18 ﬂuorodeoxyglucose
positron emission tomography were performed for the surveil-
lance of distant metastases. Once lesions suspicious for
recurrence were detected on the follow-up imaging, ﬁne-needle
aspiration, core needle biopsy, vacuum-assisted biopsy, or
excisional biopsy was performed to conﬁrm the recurrence. If
no histopathological result was obtained, follow-up imaging was
performed to evaluate interval growth or additional lesions
suspicious for recurrence.2.2. Breast MRI examination technique
All breast MRI examinations were performed using a 1.5-T
system (Symphony; Siemens Healthcare, Erlangen, Germany)
with a dedicated breast coil. Fat-suppressed T2-weighted spin-
echo sagittal images were obtained by using the following image
parameters: repetition time ms/echo time ms, 2900/150; matrix,st cancer. Bx=biopsy, CTx=chemotherapy.
Figure 2. The annual recurrence hazard rate for 602 breast cancer patients.
The hazard rates described demonstrate hazard of recurrence for each 1-year
interval.
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without gaps. Subsequently, a 3-dimensional fast low-angle shot
series was acquired (repetition time ms/echo time ms, 11.0/4.5;
matrix, 320  221; ﬂip angle, 25°; ﬁeld of view, 200  200mm;
section thickness, 2mm without gaps) was performed with 1
precontrast and 5 postcontrast dynamic series obtained immedi-
ately after intravenous administration of a bolus injection of 0.1
mmol/kg gadobutrol (Gadovist; Schering AG, Berlin, Germany)
followed by a 20-mL saline ﬂush at an injection rate of 3mL/s
using an automatic injector. Standard subtraction images were
obtained by subtracting the precontrast images from the second
dynamic series (or early peak) of postcontrast images on a pixel-
by-pixel basis. In addition, maximum-intensity-projection recon-
structions were applied to the subtraction images.
2.3. Breast MRI analysis
Two radiologists with 3 and 5 years of experience in breast MR
imaging blinded to clinical information other than breast cancer
independently reviewed DCE-MRI of the index lesion on a
picture archiving and communication system workstation
monitor (m-view; Marotech, Seoul, South Korea). In patients
with multifocal or multicentric disease, the largest focus/center
was evaluated. The radiologists analyzed background parenchy-
mal enhancement (BPE) (minimal/mild or moderate/marked) and
internal enhancement (nonrim or rim) of the index cancer
according to the second edition of Breast Imaging Reporting and
Data System (BI-RADS) MRI lexicon.[15] For adjacent vessel
signs on subtracted images, the presence of vessels either entering
the enhancing lesion or in contact with the lesion edge was
accepted as a positive adjacent vessel sign.[16] Whole-breast
vascularity of the ipsilateral breast with cancer was compared
with that of the contralateral breast at each maximum-intensity-
projection images on the basis of the number of vessels that were
3cm or longer in length and 2mmor larger in maximal transverse
diameter.[17] The degree of vascularity difference was classiﬁed as
“prominent” if the number of vessels in the ipsilateral breast was
3 or more than that of the contralateral breast; “moderate” if
higher by 2; “mild” if higher by 1; and “not increased” if the
number of vessels in the ipsilateral breast was the same as or
lower than that of the contralateral breast.[18] Time-intensity
curves of index cancers were retrospectively generated by each
radiologist with dedicated DCE-MRI software (Mean curve:
Siemens Healthcare, Erlangen, Germany). A region of interest
(ROI) was placed on the fastest-enhancing area or the area
showing the most suspicious washout curve pattern of the lesion.
For kinetic curve assessment, the initial enhancement pattern and
kinetic curve pattern were classiﬁed as slow, medium, or rapid
and as persistent, plateau, or washout, respectively.[15] In cases in
which there was discordance between the radiologists’ assess-
ments of DCE-MRI features of BPE, internal enhancement,
adjacent vessel sign, whole-breast vascularity, and kinetic curve
pattern, consensus was reached.
Quantitative kinetic parameters were derived from time-
intensity curve images. For each curve, the initial enhancement
percentage (E1), peak enhancement percentage (Epeak), and time
to peak enhancement (TTP) were measured as follows:[19]E1=
100(S1 – S0)/S0, Epeak=100 (Speak – S0)/S0, where E1 is the
initial percentage enhancement, Epeak is the peak percentage
enhancement, S1 is the signal intensity in the ROI at the ﬁrst
contrast-enhanced point, Speak is the peak signal intensity, and S0
is the unenhanced signal intensity in the ROI. Time to peak
enhancement is the time in seconds between injection of contrast3material and the peak of the signal intensity-time curve. The
signal enhancement ratio (SER) was calculated as a measure of
washout as follows:[20] SER= (S1 – S0)/(Slast – S0), where Slast is
the signal intensity in the ROI at the last point of contrast
enhancement.2.4. Clinico-pathologic features
After review of patient medical records, we compiled data on
patient age, tumor staging, axillary node status, histologic grade,
nuclear grade, existence of lymphovascular invasion and an
extensive intraductal carcinoma component, and ER, progester-
one receptor (PR), Ki-67, HER-2, p53, and cytokeratin-5
expression. ER and PR positivity was deﬁned as the presence
of 10% or more positively stained nuclei in 10 high-power ﬁelds.
Ki-67 labeling was deﬁned as negative (<14%) or positive
(≥14%). The intensity of HER-2 staining was semiquantitatively
scored as 0, 1 +, 2 +, or 3 +. Tumors with a 3 + score were
classiﬁed as HER-2-positive and tumors with a 0 or 1+ score were
classiﬁed as HER-2-negative. In tumors with a 2+ score, gene
ampliﬁcation with ﬂuorescence in situ hybridization was used to
determine HER-2 status. HER-2 expression was considered
positive if the ratio of HER-2 gene chromosome 17 signals was
>2.2. The molecular subtype of the tumor was classiﬁed into
luminal (hormonal receptor positive and HER-2 negative), triple
negative (normal receptor negative and HER-2 negative), and
HER-2 enriched (HER-2 positive).2.5. Breast cancer recurrence
The medical records of all patients were reviewed to document
early and late recurrence of breast cancer. Recurrence time was
calculated from the date of surgery to the date of ﬁrst recurrence
diagnosis. Patients with recurrence were divided into 2 groups
according to the time of recurrence: early (2.5 years after
surgery) and late (>2.5 years after surgery). The cut-off of 2.5
years was selected for stratiﬁcation because it is widely
recognized that the peak time to recurrence for breast cancer
is 2 to 3 years after diagnosis[21,22]
Table 1
Comparison of clinico-pathologic characteristics between early
and late recurrence.
Characteristics
Early
recurrence (n=47)
Late recurrence
(n=36) P
Age, y
∗
47.0 (40–57) 50.5 (42.5–59.5) 0.262
Stage 0.141
I/II 31 (66.0) 29 (80.6)
III 16 (34.0) 7 (19.4)
T stage 0.984
T1 19 (40.4) 15 (41.7)
T2 25 (53.2) 19 (52.8)
T3 3 (6.4) 2 (5.6)
N stage 0.602
N0 19 (40.4) 18 (50.0)
N1 13 (27.7) 11 (30.6)
N2 7 (14.9) 4 (11.1)
N3 8 (17.0) 3 (8.3)
Multifocality 0.918
Negative 37 (78.7) 28 (77.8)
Positive 10 (21.3) 8 (22.2)
Lymphovascular invasion 0.722
Negative 32 (88.9) 43 (91.5)
Positive 4 (11.1) 4 (8.5)
EIC 0.066
Negative 40 (85.1) 24 (66.7)
Positive 7 (14.9) 12 (33.3)
ER 0.374
Negative 24 (51.1) 14 (38.9)
Positive 23 (48.9) 22 (61.1)
PR 0.218
Negative 26 (55.3) 15 (41.7)
Positive 21 (44.7) 21 (58.3)
HER-2 0.018
Negative 33 (70.2) 16 (44.4)
Positive 14 (29.8) 20 (55.6)
Ki-67† 0.760
Negative 4 (18.2) 2 (14.3)
Positive 18 (81.8) 12 (85.7)
p53 0.437
Negative 35 (74.5) 24 (66.7)
Positive 12 (25.5) 12 (33.3)
CK5 0.276
Negative 36 (76.6) 31 (86.1)
Positive 11 (23.4) 5 (13.9)
Histologic grade 0.067
I/II 13 (27.7) 17 (47.2)
III 34 (72.3) 19 (52.8)
Nuclear grade 0.273
I/II 27 (57.5) 16 (44.4)
III 20 (42.6) 20 (55.6)
Subtype 0.054
Luminal 27 (57.5) 27 (75.0)
HER-2 enriched 8 (17.0) 7 (19.4)
Triple negative 12 (25.5) 2 (5.6)
Numbers in parentheses represent percentages.
EIC= extensive intraductal carcinoma component, ER= estrogen receptor, HER-2=human epidermal
growth factor receptor-2, CK= cytokeratin, PR=progesterone receptor.
∗
Data are presented as median (interquartile range).
† n=36 because of missing data.
Table 2
Comparison of DCE-MRI characteristics between early and late
recurrence.
Characteristics Early recurrence Late recurrence P
BPE
Minimal/mild 16 (34.0) 12 (33.3) 0.946
Moderate/marked 31 (66.0) 24 (66.7)
Internal enhancement 0.097
Non-rim 27 (57.5) 27 (75.0)
Rim 20 (42.5) 9 (25.0)
Adjacent vessel sign 0.034
Absent 14 (29.8) 19 (52.8)
Present 33 (70.2) 17 (47.2)
Whole-breast vascularity 0.033
Not increased 19 (40.4) 18 (50.0)
Mild/moderate 13 (27.7) 15 (41.7)
Prominent 15 (31.9) 3 (8.3)
Initial enhancement pattern 0.468
Rapid 38 (80.9) 25 (69.4)
Medium 7 (14.9) 8 (22.2)
Slow 2 (4.3) 3 (8.3)
Kinetic curve types 0.989
Persistent 7 (14.9) 5 (13.9)
Plateau 19 (40.4) 15 (41.7)
Washout 21 (44.7) 16 (44.4)
Quantitative parameters
E1
∗
63.7 (29.4–121.1) 59.1 (37.0–84.3) 0.332
Epeak
∗
88.7 (42.9–175.0) 78.9 (56.8–109.8) 0.751
SER
∗
0.9 (0.7–1.1) 0.8 (0.6–1.0) 0.178
TTP
∗
118.5 (62.4–195.4) 145.6 (103.0–221.5) 0.223
BPE=background parenchymal enhancement, DCE-MRI = dynamic contrast-enhanced magnetic
resonance imaging, E1= the initial enhancement percentage, Epeak=peak enhancement percentage,
SER= signal enhancement ratio, TTP= time to peak enhancement.
∗
Data are presented as median (interquartile range).
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The demographic characteristics was compared between
the group of loss to follow-up (n=92) and the enrolled group4(n=602). To compare DCE-MRI and clinico-pathologic
features between early and late recurrence and clinico-
pathologic features between the group of loss to follow-up
and the enrolled group, x2 or Fisher’s exact test was used for
categorical variables and the Wilcoxon signed rank test was
used for continuous variables. The recurrence hazard rate was
calculated by a kernel smoothing method utilizing the Nelson–-
Aalen estimates. Recurrence-free survival was measured from
the date of surgery to the earliest date of recurrence. All
observations of patients without cancer recurrence were
censored on the date of the last follow-up or the date of
nonbreast cancer death. Univariate analysis was performed to
compare DCE-MRI and clinico-pathologic features between no
recurrence and early or late recurrence groups using the log-
rank test. Univariate and multivariate Cox proportional hazard
regression analyses were performed to evaluate independent risk
factors for disease progression. All continuous covariates except
age were logarithmically transformed to minimize the inﬂuence
of extreme observations. Variables with P values < 0.2 on
univariate analysis were entered as input variables for
multivariate models. The area under the receiver operating
characteristic (ROC) curves (AUC) was calculated to measure
and compare the predictability of recurrence using DCE-MRI
features and clinico-pathologic factors selected in multivariate
analyses. All statistical analyses were performed using SAS
(version 9.3; SAS Institute, Cary, NC). Two-tailed P<0.05 was
considered statistically signiﬁcant.
Table 3
Univariate Cox proportional hazard analysis of clinico-pathologic variables.
Variables
Early recurrence Late recurrence Overall recurrence
Hazard ratio P Hazard ratio P Hazard ratio P
Age, y 0.97 (0.94–1.00) 0.038 1.00 (0.97–1.03) 0.903 0.98 (0.96–1.00) 0.095
Stage
I/II 1
III 3.28 (1.79–5.99) <0.001 1.67 (0.73–3.82) 0.222 2.58 (1.56–4.09) <0.001
T stage
T1 1 1 1
T2 2.40 (1.32–4.35) 0.004 2.55 (1.30–5.02) 0.007 2.46 (1.57–3.85) <0.001
T3 3.71 (1.10–12.55) 0.035 3.74 (0.86–16.35) 0.080 3.73 (1.45–9.54) 0.006
N stage
N0 1 1 1
N1 1.70 (0.84–3.45) 0.140 1.63 (0.77–3.46) 0.200 1.67 (0.99–2.78) 0.052
N2 2.99 (1.26–7.11) 0.013 1.94 (0.66–5.73) 0.230 2.49 (1.27–4.88) 0.008
N3 6.04 (2.64–13.79) <0.01 2.83 (0.83–9.59) 0.096 4.58 (2.33–8.98) <0.001
Multifocality
Absent 1 1 1
Present 0.82 (0.41–1.64) 0.565 0.87 (0.40–1.91) 0.727 0.84 (0.50–1.41) 0.507
Lymphovascular invasion
Negative 1 1 1
Positive 1.74 (0.84–3.62) 0.135 1.07 (0.38–3.00) 0.904 2.27 (0.80–6.44) 0.122
EIC
Negative 1 1 1
Positive 0.80 (0.58–0.89) 0.055 1.06 (0.53–2.13) 0.864 0.66 (0.39–1.10) 0.107
ER
Negative 1 1 1
Positive 0.47 (0.26–0.83) 0.009 0.78 (0.40–1.53) 0.468 0.58 (0.38–0.89) 0.014
PR
Negative 1 1 1
Positive 0.44 (0.25–0.78) 0.005 0.75 (0.39–1.45) 0.389 0.55 (0.36–0.85) 0.007
HER-2
Negative 1 1 1
Positive 0.90 (0.48–1.69) 0.747 2.87 (1.48–5.53) 0.002 1.52 (0.98–2.36) 0.060
Ki-67
∗
Negative 1 1 1
Positive 4.24 (1.44–12.54) 0.009 6.21 (1.39, 27.77) 0.017 4.89 (2.04, 11.76) <0.001
p53
Negative 1 1 1
Positive 1.08 (0.56–2.09) 0.810 1.70 (0.85–3.39) 0.135 1.33 (0.82–2.13) 0.245
CK5
Negative 1 1 1
Positive 1.63 (0.83–3.19) 0.159 1.16 (0.45–3.02) 0.755 1.44 (0.83–2.50) 0.191
Histologic grade
I/II 1 1 1
III 3.77 (1.99–7.15) <0.001 1.72 (0.89–3.31) 0.105 2.62 (1.68–4.10) <0.001
Nuclear grade
I/II 1 1 1
III 1.46 (0.82–2.60) 0.199 2.43 (1.26–4.69) 0.008 1.79 (1.22–2.64) 0.003
Subtype
Luminal 1 1 1
HER-2 enriched 1.65 (0.75–3.63) 0.215 1.39 (0.60–3.19) 0.440 1.52 (0.86–2.69) 0.151
Triple negative 2.32 (1.17–4.57) 0.016 0.37 (0.09–1.55) 0.174 1.33 (0.74–2.39) 0.348
Numbers in parentheses are 95% conﬁdence intervals.
CK= cytokeratin, EIC= extensive intraductal carcinoma component, ER= estrogen receptor, HER-2=human epidermal growth factor receptor-2, PR=progesterone receptor.
∗
Data available for 385 lesions.
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3.1. General characteristics of patients and survival
outcomes
In demographic characteristics, no signiﬁcant difference was
found between the group of loss to follow-up and the enrolled
group except patient age. The mean age of the follow-up loss5group (54.5±11.8 years) was signiﬁcantly higher than that of
enrolled group (50.9±10.4 years) (P=0.003). Among the 602
women eligible for analysis in this study, breast cancer recurred in
83 (13.8%) during the follow-up period (median 62.3 months;
range, 7.2–99.6 months): early recurrence in 47 (median 16.5
months; range, 4.0–30.0 months) and late recurrence in 36
(median 61.4 months; range 31.2–93.6 months). Themean age at
Table 4
Univariate Cox proportional hazard analysis of DCE-MRI variables.
Variables Early recurrence Late recurrence Overall recurrence
Hazard ratio P Hazard ratio P Hazard ratio P
BPE
Minimal/mild 1 1 1
Moderate/marked 1.97 (1.08–3.61) 0.027 2.36 (1.18–4.72) 0.019 2.13 (1.35–3.37) 0.001
Internal enhancement
Non-rim 1 1 1
Rim 4.51 (2.53–8.04) <0.001 2.48 (1.17–5.28) 0.018 3.56 (2.27–5.60) <0.001
Adjacent vessel sign
Absent 1 1 1
Present 1.57 (0.84–2.93) 0.159 0.64 (0.33–1.23) 0.178 1.04 (0.67–1.62) 0.864
Whole-breast vascularity
Not increased 1 1 1
Mild/moderate 1.02 (0.50–2.06) 0.963 1.29 (0.65–2.56) 0.465 1.15 (0.70–1.87) 0.588
Prominent 6.61 (3.35–13.01) <0.001 1.71 (0.50–5.81) 0.390 4.44 (2.52–7.80) <0.001
Initial enhancement
Rapid 1 1 1 0.179
Medium 1.03 (0.25–4.26) 0.971 2.77 (0.83–9.17) 0.096 1.66 (0.67–4.13) 0.276
Slow 0.54 (0.21–1.21) 0.134 0.87 (0.39–1.93) 0.737 0.68 (0.39–1.19) 0.173
Kinetic curve types
Persistent 1 1 1 0.242
Plateau 1.59 (0.67–3.79) 0.292 2.00 (0.73–5.51) 0.180 1.76 (0.91–3.40) 0.093
Washout 1.39 (0.59–3.27) 0.448 1.60 (0.59–4.38) 0.358 1.48 (0.77–2.84) 0.238
Quantitative parameters
E1 1.68 (1.39–2.03) <0.001 0.45 (0.36–0.56) <0.001 0.82 (0.66–1.02) 0.078
Epeak 0.88 (0.67–1.17) 0.387 0.75 (0.54–1.04) 0.083 0.82 (0.66–1.02) 0.074
SER 1.78 (0.91–3.48) 0.092 0.52 (0.22–1.23) 0.134 1.12 (0.61–2.06) 0.719
TTP 0.32 (0.19–0.55) <0.001 0.52 (0.29–0.94) 0.030 0.40 (0.27–0.59) <0.001
Numbers in parentheses are 95% conﬁdence intervals.
BPE=background parenchymal enhancement, DCE-MRI = dynamic contrast-enhanced magnetic resonance imaging, E1= the initial enhancement percentage, Epeak=peak enhancement percentage, SER=
signal enhancement ratio, TTP= time to peak enhancement.
Choi et al. Medicine (2016) 95:48 Medicinethe time of diagnosis was 50.9 years (range 26–80 years). Median
recurrence-free survival was 58.9 months (range 4.0–99.6
months), and the median overall survival was 59.9 months
(range 5.8–99.6 months). The shape of the annual recurrence
hazard curve over time reveals the dynamics of recurrence
(Fig. 2).
For clinico-pathologic variables (Table 1), only HER-2 status
signiﬁcantly differed between early and late recurrence. The
proportion of negative HER-2 tumors in early recurrence
(70.2%) and positive HER-2 tumors in late recurrence
(55.6%) was signiﬁcantly higher (P=0.018). For DCE-MRI
features (Table 2), adjacent vessel sign and whole-breast
vascularity signiﬁcantly differed between early and late recur-
rence. The proportion of adjacent vessel sign in early recurrence
(70.2%) was higher than that in late recurrence (47.2%) (P=
0.034). The proportion of prominent increased whole-breast
vascularity in early recurrence (31.9%) was higher than that of
late recurrence (8.3%) (P=0.033).3.2. Recurrence-free survival analysis: univariate
Among the tested clinico-pathologic variables (Table 3), stage III,
T stage ≥ T2, N stage ≥ N2, ER negativity, PR negativity, Ki-67
positivity, histologic grade III, and nuclear grade III were
signiﬁcantly associated with overall recurrence. Regarding the
time of recurrence, younger age, stage III, T stage ≥ T2, N stage ≥
N2, ER negativity, PR negativity, Ki-67 positivity, histologic
grade III, and triple-negative cancer were signiﬁcant predictors of6early recurrence. T2 stage, HER-2 positivity, Ki-67 positivity,
and nuclear grade III were signiﬁcantly associated with late
recurrence. Among the tested DCE-MRI features (Table 4),
moderate or marked BPE (hazard ratio [HR], 2.13; 95%
conﬁdence interval [CI], 1.35–3.37), rim enhancement (HR,
3.56; 95% CI, 2.27–5.60), and prominent increased ipsilateral
whole-breast vascularity (HR, 4.44; 95% CI, 2.52–7.80) were
signiﬁcantly associatedwith overall recurrence. Longer TTP (HR,
0.40; 95% CI; 0.27–0.59) was protective against overall
recurrence. Moderate or marked BPE, rim enhancement, higher
E1, and shorter TTP were signiﬁcantly associated with both early
and late recurrence. Prominent increased ipsilateral whole-breast
vascularity was signiﬁcantly associated with early recurrence.3.3. Recurrence-free survival analysis: multivariate
Among the clinico-pathologic variables tested (Table 5), stage III,
histologic grade III, and nuclear grade III were signiﬁcantly
associated with overall recurrence. For early recurrence, ER
negativity had independent predictive power. For late recurrence,
T2 stage and nuclear grade III had independent predictive power.
Among the tested DCE-MRI features (Table 5), prominent
increased ipsilateral whole-breast vascularity showed the highest
risk of overall (HR, 4.75; 95% CI, 2.54–8.91; P<0.001) and
early recurrence (HR, 2.86; 95% CI, 1.39–5.88; P=0.004)
(Fig. 3). BPE and rim enhancement were signiﬁcantly associated
with overall and late recurrence (P<0.05) (Fig. 4). Shorter TTP
was signiﬁcantly associated with overall recurrence (P=0.029)
Table 5
Multivariate Cox proportional hazard analysis of clinico-pathologic
and DCE-MRI variables.
Time of recurrence Variable Hazard ratio P
Early recurrence ER
Negative 1
Positive 0.53 (0.29–0.96) 0.038
Whole-breast vascularity
Not increased 1
Mild/moderate 1.29 (0.63–2.63) 0.493
Prominent 2.86 (1.39–5.88) 0.004
Late recurrence T stage 0.048
T1 1
T2 2.08 (1.04–4.16) 0.038
T3 3.84 (0.88–16.79) 0.075
Nuclear grade
I/II 1
III 2.54 (1.29–4.98) 0.007
BPE
Minimal/mild 1
Moderate/marked 2.08 (1.04–4.19) 0.040
Internal enhancement
Non-rim 1
Rim 2.14 (1.00–4.59) 0.049
Overall recurrence Stage
I/II 1
III 1.74 (1.14–2.83) 0.031
Histologic grade
I/II 1
III 1.92 (1.14–2.83) 0.006
Nuclear grade
I/II 1
III 1.79 (1.14–2.83) 0.012
BPE
Minimal/mild 1
Moderate/marked 2.32 (1.44–3.74) 0.001
Internal enhancement
Non-rim 1
Rim 2.84 (1.80–4.48) <0.001
Whole-breast vascularity
Not increased 1
Mild/moderate 0.89 (0.54–1.47) 0.647
Prominent 4.75 (2.54–8.91) <0.001
TTP 0.63 (0.41–0.95) 0.029
Numbers in parentheses are 95% conﬁdence intervals.
BPE=background parenchymal enhancement, DCE-MRI = dynamic contrast-enhanced magnetic
resonance imaging, ER=estrogen receptor, TTP= time to peak enhancement.
Figure 3. (A) Maximum-intensity-projection image from a 39-year-old woman
shows 5 vessels (arrows) in the left that which were interpreted as prominent
increased ipsilateral whole-breast vascularity compared with contralateral
breast. After surgery, the cancer was conﬁrmed to be stage IIB (T2N1M0), ER-
negative, PR-negative, HER-2-positive invasive ductal carcinoma with nuclear
grade 2, and histologic grade 3. (B) Follow-up breast ultrasonography obtained
after 20.3 months shows a 1-cm-sized internal mammary lymph node (arrows)
conﬁrmed to be lymph node metastasis of breast cancer by ﬁne-needle
aspiration. ER = estrogen receptor, PR = progesterone receptor, HER-2 =
human epidermal growth factor receptor 2.
Choi et al. Medicine (2016) 95:48 www.md-journal.comIn breast cancer recurrence, the AUC of DCE-MRI features
were higher for early recurrence and overall recurrence and lower
for late recurrence than that of clinico-pathologic variables.
However, no signiﬁcant differences were found (Table 6).4. Discussion
In this study, we found that prominent increased ipsilateral
whole-breast vascularity was associated with early breast cancer
recurrence and that moderate or marked BPE and rim
enhancement were associated with late recurrence in DCE-
MRI. In predicting early, late, or overall recurrence, preoperative
DCE-MRI features showed similar performance to clinico-
pathologic variables.
In general, vascular blood ﬂow provides nutrients for tumor
growth as well as a mechanism for hematogenous spread of
malignant cells. It is unsurprising that tumor aggressiveness and7breast cancer recurrence are critically dependent on tumor
angiogenesis.[23] The prevalence of increased whole-breast
vascularity associated with cancer in DCE-MRI may be due to
reduced ﬂow resistance in the tumor vessels, higher tumor
metabolism, angiogenic stimulation of the whole breast, or a
combination of these factors. In addition, a previous study
reported that increased whole-breast vascularity was frequently
present in patients with multifocal disease and large tumor size
and in patients with metastatic disease in the axillary nodes,
indicating poor prognosis.[24] Therefore, it can be hypothesized
that increased vascular blood ﬂowwithin a cancer-bearing breast
may be a reﬂection of the growth and metastatic potential of a
primary breast tumor, which can seed tumor cells into the
peripheral blood, eventually increasing the probability of early
recurrence.
Moderate or marked BPE was found to be a signiﬁcant DCE-
MRI feature predictive of late and overall recurrence in this
study. BPE is due to increased T1 relaxation of tissue after
gadolinium administration and the degree of BPE is directly
associated with vascular supply and permeability. Additionally,
parenchymal enhancement around a tumor on preoperative
DCE-MRI may reﬂect the status of the microenvironment that
is associated with cancer recurrence following breast-conserv-
ing treatment.[25] A relatively higher BPE around the breast
cancer in the recurrence group indicates increased endothelial
permeability that allows the contrast agent to move to and from
[25]
Figure 4. (A) Subtraction image on T1-weighted contrast-enhanced breast
MR imaging from a 43-year-old woman shows an irregular mass with rim
enhancement and moderate degree of background parenchymal enhance-
ment. After surgery, the cancer was conﬁrmed to be stage IIA (T1N1M0),
ER-positive, PR-positive, HER-2-positive invasive ductal carcinoma with
nuclear grade 3, and histologic grade 1. (B) Follow-up PET/CT obtained after
37.5 months shows focal areas of increased 18F-FDG uptake in right
acetabulum, corresponding to bone metastasis. ER = estrogen receptor, PR =
progesterone receptor, HER-2 = human epidermal growth factor receptor 2,
PET/CT = positron emission tomography/computed tomography.
Choi et al. Medicine (2016) 95:48 Medicinevessels surrounding the tumor. In other words, increased
endothelial permeability results in a higher probability of direct
interaction of breast cancer cells and vasculature, thereby
facilitating tumor growth and metastasis. Although prominent
increased whole-breast vascularity and BPE have similar mecha-Table 6
Area under the receiver operating characteristic curve based on sele
Variables Clinico-pathologic factors
Early recurrence 0.62 (0.49–0.75)
Late recurrence 0.69 (0.61–0.77)
Overall recurrence 0.68 (0.62–0.74)
Numbers in parentheses are 95% conﬁdence intervals.
DCE-MRI = dynamic contrast-enhanced magnetic resonance imaging.
8nisms for breast cancer recurrence, BPE was associated with late
recurrence, unlike prominent increased whole-breast vascularity,
which was associated with early recurrence. Despite a recent surge
in investigation of tumor angiogenesis, the effects of large-vessel
angiogenesis, including whole-breast vascularity, remain largely
unknown. One possibility is that angiogenic stimulation by breast
cancer involves not onlymicrovessels, but also larger vessels.More
large-vessel angiogenesis might facilitate tumor growth and
development of early breast cancer recurrence more effectively,
with lower ﬂow resistance than increased endothelial permeability
of small vessels.
Rim enhancement on DCE-MRI was found to predict late and
overall recurrence in this study. This MR feature is caused by a
lower microvessel density within the tumor rather than an
elevated microvessel density in the periphery of tumor. In
addition, rim enhancement is correlated with tumor ﬁbrosis and
necrosis.[6] A central ﬁbrotic focus in breast cancer that is
correlated with rim enhancement is a marker of intratumoral
hypoxia and its size is correlated with lower microvessel density
within the tumor and higher histologic grade.[26–28] However, the
relationship between microvessel density, intratumoral hypoxia,
and late recurrence of breast cancer remains poorly understood.
Several studies have shown a correlation between rim enhance-
ment and rapid tumor growth, decreased tumor differentiation,
and other poor prognostic features such as a higher histological
grade, ER negativity, higher expression of Ki-67, and higher
lymph node stage.[6,7,14,19] Among these poor prognostic
features, lymph node status is associated with late recurrence,
as is rim enhancement on DCE-MRI.[8]
Among the clinico-pathologic variables investigated in this
study, ER-negativity was associated with early breast cancer
recurrence, which is similar to what was found in a previous
study reporting that ER-positivity conferred a signiﬁcantly lower
recurrence risk than ER-negativity in the 2-year follow-up
period.[29] For late recurrence, we observed an independent
association with T2 stage and high nuclear grade. In general,
tumor size is a well-known important prognostic factor for
recurrence.[10] Unlike T2 stage, however, the T3 stage was not
independently associated with late recurrence in this study. This
might be attributed to a small number of patients with T3 cancer.
A previous study reported that high nuclear grade was associated
with early metastasis, which is not consistent with our results.[30]
However, the cut-off between early and late recurrence was 3.7
years in the previous study, which is different from the 2.5 years
used in our study. If we consider this difference in cut-off time,
our results are consistent with this previous study.
In terms of the performance in predicting breast cancer
recurrence of DCE-MRI features and clinico-pathologic varia-
bles, there were no signiﬁcant differences in the AUC between
DCE-MRI features and clinico-pathologic variables for early,
late, and overall recurrence (Table 6). In practice, the clinico-
pathologic variables associated with recurrence can only bected DCE-MRI and clinico-pathologic variables.
DCE-MRI features P
0.63 (0.50–0.76) 0.886
0.62 (0.53–0.71) 0.261
0.73 (0.67–0.73) 0.271
[9] Nishimura R, Osako T, Nishiyama Y, et al. Evaluation of factors related
Choi et al. Medicine (2016) 95:48 www.md-journal.comobtained after surgery and are thus not useful for preoperative
prediction of breast cancer recurrence. Although some clinico-
pathologic variables such as histologic grade or nuclear grade can
be available even after core needle biopsy, there is still the issue of
discordant results between core needle biopsy and surgical
excision. However, DCE-MRI is a noninvasive imaging modality
for preoperative evaluation of tumor characteristics and staging
through tumor vascularity. Therefore, our results suggest that
DCE-MRI features could be useful for preoperative prediction of
early, late, and overall recurrence.
This study has some limitations. First, this study included a
small number of patients with breast cancer recurrence from a
single institution. Therefore, our patients might not be
representative of the general population. Second, this study
was retrospective and the follow-up period was not long
enough (median follow-up, 62.3 months), considering that the
luminal subtype of breast cancer may recur even after 10 years.
Third, 13% of the eligible 694 patients were lost to follow-up,
which might have introduced bias. However, no signiﬁcant
difference was found between the group of loss to follow-up
and the enrolled group in clinico-pathologic features except
patient age. The age difference between 2 groups would be
unlikely to affect the study results. Fourth, we did not evaluate
the status of adjuvant hormonal therapy or adjuvant
chemotherapy, which could have affected the recurrence
period. Lastly, MR imaging was not scheduled according to
the women’s menstrual cycles, which could have affected the
BPE. Although scheduling of screening MR imaging in the
second week of a woman’s menstrual cycle is routinely
recommended to minimize the effect of BPE, diagnostic MR
imaging for staging of breast cancer is usually performed
regardless of the menstrual cycle.
In conclusion, prominent increased whole-breast vascularity
for early recurrence and moderate or marked BPE and rim
enhancement for late recurrence on DCE-MRI could be useful for
preoperative prediction of early and late recurrences and to
establish an appropriate follow-up protocol.References
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